首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.
【2h】

Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

机译:华法林和乙酰香豆酚对映异构体的人肝微粒体代谢:P450同工酶多样性决定了它们药代动力学的差异。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. To explain the large differences in (the stereoselectivity of) the clearances of the enantiomers of warfarin and acenocoumarol (4'-nitrowarfarin) their human liver microsomal metabolism has been studied and enzyme kinetic parameters determined. The effects of cimetidine, propafenone, sulphaphenazole, and omeprazole on their metabolism has been investigated. 2. The 4-hydroxycoumarins follow similar metabolic routes and are mainly hydroxylated at the 6- and 7-position (accounting for 63 to 99% of the metabolic clearances). 3. Due to the lower Km values of R- and S-acenocoumarol and higher Vmax values of S-acenocoumarol, the overall metabolic clearances of R/S acenocoumarol exceed those of R/S warfarin 6 and 66 times respectively. 4. The metabolism of both compounds is stereoselective for the S-enantiomers, which is 10 times more pronounced in the case of acenocoumarol. 5. Except for the 7-hydroxylation of the R-enantiomers (r = 0.90; P < 0.025), the 6- and 7-hydroxylation rates of R/S warfarin do not correlate with those of R/S acenocoumarol. 6. Sulphaphenazole competitively inhibits the 7- and in some samples partly (up to 50%) the 6-hydroxylation of S-warfarin as well as the 7-hydroxylation of R- and S-acenocoumarol and the 6-hydroxylation of S-acenocoumarol (Kis ranging from 0.5-1.3 microM). 7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.(ABSTRACT TRUNCATED AT 250 WORDS)
机译:1.为了解释华法林和乙酰香豆酚(4'-硝基华法林)对映异构体的清除率(立体选择性)存在很大差异,已研究了它们的人肝微粒体代谢并确定了酶动力学参数。研究了西咪替丁,普罗帕酮,磺胺苯并恶唑和奥美拉唑对其代谢的影响。 2. 4-羟基香豆素遵循相似的代谢途径,主要在6位和7位羟基化(占代谢清除率的63%至99%)。 3.由于R-和S-乙酰香豆酚的Km值较低,S-乙酰香豆酚的Vmax值较高,R / S乙酰香豆酚的总代谢清除率分别比R / S华法林的清除率高出6倍和66倍。 4.两种化合物的代谢对S-对映异构体都是立体选择性的,在乙酰香豆酚的情况下,这是10倍以上。 5.除了R-对映异构体的7-羟基化(r = 0.90; P <0.025)外,R / S华法林的6-羟基和7-羟基化速率与R / S乙酰香豆酚的速率不相关。 6. Sulphaphenazole竞争性抑制S-华法林的7-羟基化,在某些样品中(部分高达50%)抑制R-和S-乙酰香豆酚的7-羟基化以及S-乙酰香豆酚的6-羟基化(Kis范围从0.5-1.3 microM)。 7.奥美拉唑部分(40-80%)抑制R-华法林(Ki = 99和117 microM)和R-(Ki = 219和7.2 microM)和S-乙酰香豆酚(Ki = 6.1)的6-和7-羟基化作用和7.7 microM)而非竞争性方式的S-华法林。(摘要截短为250字)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号